News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
28.01 ^USD	-2.91%		+0.25%	-30.62%

May. 29	Transcript : BridgeBio Pharma, Inc. - Special Call
May. 28	UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study	May. 30	AQ
Transcript : BridgeBio Pharma, Inc. - Special Call	May. 29
BridgeBio Pharma : BBIO Acoramidis (AG10) TTR ISA 2024 Featured research in the ATTR CM landscape	May. 29	PU
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	May. 29	GL
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Rationale & design of ACT-EARLY	May. 29	PU
UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating	May. 28	MT
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting	May. 24	GL
BridgeBio Pharma : BBIO BBP 418 – MENA 2024 – Oral Presentation	May. 20	PU
Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
BridgeBio Pharma : Bank of America Merrill Lynch Healthcare Conference 2024 Presentation	May. 15	PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	May. 15	GL
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024	May. 14	GL
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population	May. 13	GL
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population	May. 13	CI
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – NT-proBNP Insights from the ATTRibute-CM Study	May. 13	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM	May. 11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Summary

Filters